Comparative Pharmacology
Head-to-head clinical analysis: NOVOLOG MIX 50 50 versus NOVOLOG PENFILL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVOLOG MIX 50 50 versus NOVOLOG PENFILL.
NOVOLOG MIX 50/50 vs NOVOLOG PENFILL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin analog with rapid onset of action due to substitution of amino acid proline with aspartic acid at position B28, facilitating faster dissociation from hexamers into monomers after subcutaneous injection. Biphasic formulation containing 50% insulin aspart protamine (intermediate-acting) and 50% insulin aspart (rapid-acting).
Insulin aspart is a rapid-acting recombinant human insulin analog. It lowers blood glucose by binding to insulin receptors on skeletal muscle and adipose tissue, promoting glucose uptake, and inhibiting hepatic glucose production via glycogenolysis and gluconeogenesis.
Subcutaneous injection. Typical adult dose: 0.5 to 1 unit/kg/day divided into two injections (with breakfast and dinner). Dose is individualized based on blood glucose levels and patient needs.
Subcutaneous injection: 0.5-1 unit/kg/day divided into multiple doses (e.g., basal-bolus regimen). Individualized based on glucose monitoring.
None Documented
None Documented
6-8 hours (terminal half-life of protamine-bound fraction; free insulin component half-life ~4-5 minutes).
~5-7 minutes (free insulin aspart); clinical effect duration correlates with SC absorption half-life ~1-2 hours
Renal: 50-60% as intact insulin, 30-40% as metabolites; biliary/fecal: minimal (<1%).
Renal: 60-80% as metabolites; unchanged drug excreted minimally. Fecal: <10%
Category C
Category C
Insulin Analog
Insulin Analog